

# CURRICULUM VITAE

**Dr. Filip Miljković**

Gothenburg, Sweden

Tel: +46 (0) 736859184, E-mail: [filipm90@yahoo.com](mailto:filipm90@yahoo.com), Website: [filipm90.github.io](http://filipm90.github.io)

[LinkedIn](#) [ORCID](#) [ResearchGate](#)

## Work Experience *January 2021 – Present*

### **Affiliate Scientist**

Department of Life Science Informatics, b-it, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany

### *February 2020 – Present*

### **Senior Data Scientist**

Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences, AstraZeneca R&D, Gothenburg, Sweden

## Education *June 2016 – December 2019*

### **Ph.D. (Dr. rer. nat.) in Computational Life Sciences**

Department of Life Science Informatics, b-it, LIMES Program Unit Chemical Biology and Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany

Grade: 0.7 (*Magna cum laude*)

Thesis: Chemoinformatics-Driven Approaches for Kinase Drug Discovery

Supervisor: Prof. Jürgen Bajorath

### *October 2009 – September 2014*

### **Master degree in Pharmacy (Integrated studies)**

Department of Pharmacy, Faculty of Medicine, University of Niš, Serbia

Grade: 9.58/10.00

Thesis: An Overview of Dipeptidyl Peptidase-IV Inhibitors

Supervisor: Prof. Andrija Šmelcerović

## International Experience *July 2013 – August 2013*

### **IPSF Student Exchange Programme**

Department of Analytical Chemistry, Medical University of Gdańsk, Poland

Description: Quality consistency evaluation of *Melissa officinalis* L. samples using HPLC fingerprints

Supervisor: Agnieszka Viapiana, PhD

## Technical Skills

Data extraction/curation (KNIME, RDKit and OpenEye Chemistry Toolkit), SAR analysis, Network analysis (Cytoscape, Gephi, NetworkX Python package), 2D/3D ligand similarity, Structure and Ligand-based virtual screening, Molecular modeling suites (MOE), Docking (MOE Dock, AutoDock, PLANTS, DockTite for covalent docking), Protein-ligand interaction fingerprints, Machine

learning (SVM, RF, XGB, DNN, GCNN; scikit-learn, TensorFlow)

**Computer Skills** Python (advanced knowledge), Bash (basic knowledge), R (basic knowledge), SQL (basic knowledge), ChemOffice, Biovia, KNIME/Pipeline Pilot, Office suite, Windows/Linux

**Languages** Serbian (native)  
English (fluent): TOEFL (109/120)  
Swedish (good)  
German (good)

**Teaching Experience** **Master's Program in Pharmacy at the Medical faculty, University of Niš, Serbia**

- "General Chemistry with Stoichiometry", October 2010 – January 2011.
- "Organic Chemistry", March 2011 – June 2011.

**Master's Program in Life Science Informatics at the University of Bonn, Germany**

- "Introduction to Chemistry", September 2016 – October 2016.
- "Structural Bioinformatics", October 2016 – January 2018.
- "Molecular Modeling and Drug Design", April 2017 – February 2019.
- "Programming Lab I" (Python), April 2019 – June 2019.
- "Introduction to Machine Learning Tutorial", April 2019 – June 2019.
- Supervision of Master Thesis, Mariana González-Medina, 2019.

**Visiting Students Coming from Collaborative Projects between University of Bonn, Germany and Kyoto University, Japan or Waseda University, Japan**

- "Structural Bioinformatics and Molecular Modeling", October 2017 – December 2019.

**Publications**

25. Rodríguez-Pérez, R.; **Miljković, F.**; Bajorath, J. Machine Learning in Chemoinformatics and Medicinal Chemistry. *Ann. Rev. Biomed. Data Sci.* **2022**, *in press*.

24. Laufkötter, O.; Hu, H.; **Miljković, F.**; Bajorath, J. Structure- and Similarity-Based Survey of Allosteric Kinase Inhibitors, Activators, and Closely Related Compounds. *J. Med. Chem.* **2022**, *in press*.

23. **Miljković, F.**; Rodríguez-Pérez, R.; Bajorath, J. Impact of Artificial Intelligence on Compound Discovery, Design, and Synthesis. *ACS Omega* **2021**, *6*, 33293-33299.

22. **Miljković, F.**; Martinsson, A.; Obrezanova, O.; Williamson, B.; Johnson, M.; Sykes, A.; Bender, A.; Greene, N. Machine Learning Models for Human *In Vivo* Pharmacokinetic Parameters with In-House Validation. *Mol. Pharmaceutics* **2021**, *18*, 4520-4530.

21. Hu, H.; Laufkötter, O.; **Miljković, F.**; Bajorath, J. Data Set of Competitive and Allosteric Protein Kinase Inhibitors Confirmed by X-ray Crystallography. *Data in Brief* **2021**, *35*, e106816.

20. Hu, H.; Laufkötter, O.; **Miljković, F.**; Bajorath, J. Systematic Comparison of Competitive and Allosteric Kinase Inhibitors Reveals Common Structural Characteristics. *Eur. J. Med. Chem.* **2021**, *214*, e113206.
19. **Miljković, F.**; Chaudhari, R. Members of our Early Career Panel Highlight Key Research Articles on the Theme of Computer-Aided Drug Design. *Future Drug Discov.* **2020**, *2*, FDD52.
18. Rodríguez-Pérez, R.; **Miljković, F.**; Bajorath, J. Assessing the Information Content of Structural and Protein–Ligand Interaction Representations for the Classification of Kinase Inhibitor Binding Modes via Machine Learning and Active Learning. *J. Cheminform.* **2020**, *12*, e36.
17. **Miljković, F.**; Xiong, R.; Sivakumar, D.; Brown, C. A. Members of our Early Career Panel Highlight Key Research Articles on the Theme of Drug Repurposing. *Future Drug Discov.* **2020**, *2*, FDD39.
16. **Miljković, F.**; Rodríguez-Pérez, R.; Bajorath, J. Machine Learning Models for Accurate Prediction of Kinase Inhibitors with Different Binding Modes. *J. Med. Chem.* **2020**, *63*, 8738–8748.
15. **Miljković, F.**; Bajorath, J. Data Structures for Computational Compound Promiscuity Analysis and Exemplary Applications to Inhibitors of the Human Kinome. *J. Comput. Aided Mol. Des.* **2020**, *34*, 1–10.
14. González-Medina, M.; **Miljković, F.**; Haase, G. S.; Drueckes, P.; Trappe, J.; Laufer, S.; Bajorath, J. Promiscuity Analysis of a Kinase Panel Screen with Designated p38 alpha Inhibitors. *Eur. J. Med. Chem.* **2020**, *187*, 112004.
13. Feldmann, C.; **Miljković, F.**; Yonchev, D.; Bajorath, J. Identifying Promiscuous Compounds with Activity Against Different Target Classes. *Molecules* **2019**, *24*, e4185.
12. **Miljković, F.**; Bajorath, J. Data Structures for Compound Promiscuity Analysis: Cliffs, Pathways, and Hubs Formed by Inhibitors of the Human Kinome. *Future Sci. OA* **2019**, *5*, FSO404.
11. **Miljković, F.**; Vogt, M.; Bajorath, J. Systematic Computational Identification of Promiscuity Cliff Pathways Formed by Inhibitors of the Human Kinome. *J. Comput. Aided Mol. Des.* **2019**, *33*, 559–572.
10. Blaschke, T.; **Miljković, F.**; Bajorath, J. Prediction of Different Classes of Promiscuous and Nonpromiscuous Compounds Using Machine Learning and Nearest Neighbor Analysis. *ACS Omega* **2019**, *4*, 6883–6890.
9. **Miljković, F.**; Bajorath, J. Computational Analysis of Kinase Inhibitors Identifies Promiscuity Cliffs across the Human Kinome. *ACS Omega* **2018**, *3*, 17295–17308.
8. **Miljković, F.**; Bajorath, J. Data-Driven Exploration of Selectivity and Off-Target Activities of Designated Chemical Probes. *Mol.* **2018**, *23*, e2434.
7. **Miljković, F.**; Bajorath, J. Evaluation of Kinase Inhibitor Selectivity Using Cell-Based Profiling Data. *Mol. Inform.* **2018**, *37*, e1800024.
6. **Miljković, F.**; Bajorath, J. Reconciling Selectivity Trends from a Comprehensive Kinase Inhibitor Profiling Campaign with Known Activity Data. *ACS Omega* **2018**, *3*, 3113–3119.
5. **Miljković, F.**; Bajorath, J. Exploring Selectivity of Multikinase Inhibitors across the Human Kinome. *ACS Omega* **2018**, *3*, 1147–1153.
4. **Miljković, F.**; Kunimoto, R.; Bajorath, J. Identifying Relationships between Unrelated Pharmaceutical Target Proteins on the Basis of Shared Active Compounds. *Future Sci. OA* **2017**, *3*, FSO212.
3. Smelcerovic, A.; **Miljkovic, F.**; Kolarevic, A.; Lazarevic, J.; Djordjevic, A.; Kocic, G.; Anderluh, M. An Overview of Recent Dipeptidyl Peptidase-IV Inhibitors:

Linking Their Structure and Physico-Chemical Properties with SAR, Pharmacokinetics and Toxicity. *Curr. Top. Med. Chem.* **2015**, 15, 2342-2372.

2. Toropov, A. A.; Veselinović, J. B.; Veselinović, A. M.; **Miljković, F. N.**; Toropova, A. P. QSAR Models for 1,2,4-Benzotriazines as Src Inhibitors Based on Monte Carlo Method. *Med. Chem. Res.* **2015**, 24, 283-290.

1. Toropova, A. P.; Toropov, A. A.; Veselinović, J. B.; **Miljković, F. N.**; Veselinović, A. M. QSAR Models for HEPT Derivates as NNRTI Inhibitors Based on Monte Carlo Method. *Eur. J. Med. Chem.* **2014**, 77, 298-305.

**Selected  
Abstracts and  
Conference  
Publications**

3. "Proceedings of IEEE International Conference on Bioinformatics and Biomedicine (BIBM 2021). IEEE International Conference on Bioinformatics and Biomedicine (BIBM 2021)", December 9-12, 2021, Institute of Electrical and Electronics Engineers (IEEE), Virtual. Conference Paper: Bai, P.; **Miljković, F.**; Ge, Y.; Greene, N.; John B.; Lu. H. "Hierarchical Clustering Split for Low-Bias Evaluation of Drug-Target Interaction Prediction".

2. "19<sup>th</sup> International Workshop on (Q)SAR in Environmental and Health Sciences – QSAR 2021 From QSAR to New Approach Methodologies (NAMs)", June 7-9, 2021, American Society for Cellular and Computational Toxicology (ASCCT), Virtual. Oral Presentation: **Miljković, F.**; Martinsson, A.; Obrezanova, O.; Williamson, B.; Johnson, M.; Oprisiu, I.; Bender, A.; Greene N. "Machine Learning Models for Predicting Human *In Vivo* PK Parameters Using Chemical Structure and Dose".

1. "Chemoinformatics Strasbourg Summer School", June 25-29 June 2018, University of Strasbourg, Strasbourg, France. Poster: **Miljković, F.**; Bajorath, J. "Exploring Selectivity of Multi-kinase Inhibitors across the Human Kinome", awarded as the best poster by public choice.